The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of INmune Bio Inc (NASDAQ: INMB) closed at $2.68 in the last session, down -15.19% from day before closing price of $3.16. In other words, the price has decreased by -$15.19 from its previous closing price. On the day, 2.14 million shares were traded. INMB stock price reached its highest trading level at $3.0 during the session, while it also had its lowest trading level at $2.5746.
Ratios:
We take a closer look at INMB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.64 and its Current Ratio is at 2.64. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On January 28, 2025, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $23.Rodman & Renshaw initiated its Buy rating on January 28, 2025, with a $23 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 30 ’24 when Moss David J bought 10,000 shares for $5.29 per share. The transaction valued at 52,868 led to the insider holds 1,285,869 shares of the business.
Tesi Raymond Joseph bought 15,380 shares of INMB for $98,048 on Sep 12 ’24. The President and CEO now owns 1,554,106 shares after completing the transaction at $6.38 per share. On Sep 12 ’24, another insider, Moss David J, who serves as the Chief Financial Officer of the company, bought 7,690 shares for $6.38 each. As a result, the insider paid 49,024 and bolstered with 1,275,869 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INMB now has a Market Capitalization of 73003472 and an Enterprise Value of 43213812. For the stock, the TTM Price-to-Sale (P/S) ratio is 1424.98 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 864.276.
Stock Price History:
The Beta on a monthly basis for INMB is 1.00, which has changed by -0.66118836 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, INMB has reached a high of $11.64, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is -48.05%, while the 200-Day Moving Average is calculated to be -58.10%.
Shares Statistics:
According to the various share statistics, INMB traded on average about 2.91M shares per day over the past 3-months and 2744870 shares per day over the past 10 days. A total of 22.93M shares are outstanding, with a floating share count of 18.90M. Insiders hold about 28.90% of the company’s shares, while institutions hold 27.95% stake in the company. Shares short for INMB as of 1752537600 were 5527466 with a Short Ratio of 1.90, compared to 1749772800 on 7256955. Therefore, it implies a Short% of Shares Outstanding of 5527466 and a Short% of Float of 24.33.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of INmune Bio Inc (INMB) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.21 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.22 and -$1.59 for the fiscal current year, implying an average EPS of -$1.45. EPS for the following year is -$1.12, with 5.0 analysts recommending between -$0.5 and -$1.87.
